GlassScriptPhysician profile
Gray Ndive Akoegbe
NPI 1043659840
$4,979.53
in general payments reported to CMS, 2019-2025
25 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $336 · 2021: $165 · 2022: $866 · 2023: $928 · 2024: $1,235 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,476.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $701.79 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $457.98 | 2019-2025 | Farxiga, Lokelma |
| Boston Scientific Corporation | $442.71 | 2020-2025 | General - Therapies, Avvigo Guidance System, Watchman Flx |
| Heartflow, INC. | $434.92 | 2022-2025 | Ffrct |
| Boehringer Ingelheim Pharmaceuticals, INC. | $351.26 | 2020-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $325.54 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $319.70 | 2019-2025 | Lifevest |
| Amgen INC. | $289.79 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $288.83 | 2021-2024 | Camzyos, Eliquis |
| Pfizer INC. | $269.12 | 2020-2025 | |
| Lexicon Pharmaceuticals, INC. | $167.62 | 2023-2024 | Inpefa |
| Medtronic, INC. | $162.97 | 2024 | Symplicity G3 |
| Abbott Laboratories | $132.66 | 2022-2025 | Xience Skypoint, Cardiomems |
| Novo Nordisk INC | $123.20 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $78.73 | 2022-2024 | Verquvo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $75.56 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Cvrx, INC. | $73.86 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.65 | 2025 | |
| Imperative Care, INC | $58.46 | 2025 | Symphony Catheter |
| Sanofi-Aventis U.S. LLC | $49.94 | 2019-2020 | |
| Innovation Technologies INC | $24.73 | 2025 | Irrisept |
| Abiomed | $21.97 | 2025 | |
| Medtronic Vascular, INC. | $21.29 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $18.21 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $16.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gray Akoegbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.